$SNSS News
Last published 5y ago
- 5y agoSNSSViracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated LymphomaPR NewswireViracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U....
- 5y agoSNSSViracta Therapeutics to Participate in Upcoming Virtual Investor ConferencesPR NewswireViracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the...
- 5y agoSNSSViracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDAPR NewswireViracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent...
- 5y agoHDSGVCLCTSNSSMoore Kuehn Encourages HDS, GV, CLCT and SNSS Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 5y agoSNSSSunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger AgreementGlobeNewswireMerger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in...
- 5y agoSNSSSunesis Pharmaceuticals, Inc. (SNSS) Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 5y agoSNSSSunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ended September 30, 2020. Loss from...
- 6y agoSNSSSunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at...
- 6y agoSNSSSunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular...
- 6y agoSNSSSunesis Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor...
- 6y agoSNSSSunesis Pharmaceuticals Announces 1-for-10 Reverse Stock SplitGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...
- 6y agoSNSSSunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from...
- 6y agoSNSSSunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30...
- 6y agoSNSSSunesis Announces Pricing of $12 Million Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its...
- 6y agoSNSSSunesis Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...
- 6y agoSNSSSunesis Pharmaceuticals Provides Corporate UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus...
- 6y agoSNSSSunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib ProgramGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor...
- 6y agoSNSSSunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2020. Loss from...
- 6y agoSNSSSunesis Pharmaceuticals to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, March 10, 2020 at 4:30...
- 6y agoSNSSSunesis Pharmaceuticals to Present at the 40th Annual Cowen Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
- 6y agoEVLOZIOPSNSSVor Biopharma Expands Leadership Team with Chief Legal Officer and Vice President of PeopleBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced two additions to its leadership. Seasoned patent attorney Amy Mendel joins Vor as Chief Legal Officer and human resources executive Tania Philipp joins as Vice President of People. These experienced life sciences specialists conti ...
- 6y agoSNSSSunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell MalignanciesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK...
- 7y agoSNSSSunesis Pharmaceuticals, Inc. (SNSS) Management on Q3 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoSNSSSunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
- 7y agoSNSSSunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61st American Society of Hematology (ASH)...
- 7y agoSNSSSunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference...
- 7y agoSNSSSunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of...
- 7y agoSNSSSunesis Pharmaceuticals, Inc. (SNSS) Interim CEO Dayton Misfeldt on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoSNSSSunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoSNSSSunesis Pharmaceuticals' (SNSS) Management on Q1 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoSNSSSunesis' (SNSS) CEO Dan Swisher on Q3 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoSNSSSunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q2 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoSNSSSunesis Pharmaceuticals' (SNSS) CEO Dan Swisher on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoSNSSSunesis Pharmaceuticals (SNSS) Q4 2015 Results - Earnings Call WebcastEarnings Call Transcripts